Altrix Bio

Surgery In A Pill™

About this Event

AltrixBio is developing LuCI™, a patent-protected oral drug for obesity and Type 2 Diabetes (T2D) that reproduces the metabolic benefits of gastric bypass surgery for treating obesity and T2D. LuCI, when taken before a meal, temporarily coats the stomach and small intestine, forming a barrier, similar to what happens in gastric bypass surgery.

In pre-clinical testing, LuCI demonstrated decreased body weight, improved glucose control and insulin sensitivity, increased endogenous GLP-1 and GIP secretion, and positively impacted cardiovascular markers. The company believes that LuCI™ will be well tolerated and a complementary solution for patients who cannot tolerate the GLP-1 medications (50% come off the meds in the first year), do not want an injectable solution, or to maintain weight loss and glycemic control when stopping a GLP-1 medication.

LuCI is based on Sucralfate and is used today for stomach and gastric ulcers. It has a clean safety profile and has been prescribed by PCPs for more > than 30 years. Sucralfate does not enter the bloodstream and has never had a lethal dose. It is one of the safer drugs prescribed today.

Watch the webinar with AltrixBio President and CEO, Nancy Briefs, to hear how this oral medication will challenge Ozempic, Wegovy, and Mounjaro as a first line treatment obesity and Type 2 Diabetes.

Video On Demand

– Recorded

January 16


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.